New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 7, 2012
10:05 EDTAKR, MCD, MPEL, SYT, RHHBY, TSM, DST, AET, ATHNOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Acadia Realty Trust (AKR) upgraded to Outperform from Market Perform at BMO Capital... McDonald's (MCD) upgraded to Buy from Neutral at Janney Capital... Melco Crown (MPEL) upgraded to Overweight from Neutral at JPMorgan... Syngenta (SYT) upgraded to Neutral from Underweight at JPMorgan...Roche (RHHBY) upgraded to Overweight from Equal Weight at Morgan Stanley... TSMC (TSM) upgraded to Outperform from Neutral at Credit Suisse... DST Systems (DST) upgraded to Buy from Neutral at Sterne Agee... Aetna (AET) upgraded to Overweight from Neutral at JPMorgan... athenahealth (ATHN) upgraded to Outperform from Market Perform at Leerink.
News For AKR;MCD;MPEL;SYT;RHHBY;TSM;DST;AET;ATHN From The Last 14 Days
Check below for free stories on AKR;MCD;MPEL;SYT;RHHBY;TSM;DST;AET;ATHN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 16, 2014
10:48 EDTTSMTSMC falls, levels to watch
Subscribe for More Information
10:00 EDTTSMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:00 EDTSYTOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:08 EDTTSMTSMC downgraded to Negative from Neutral at Susquehanna
06:26 EDTRHHBYBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
06:18 EDTTSMTSMC volatility increases as shares trade near 14-year high
Subscribe for More Information
05:49 EDTTSMStocks with implied volatility movement; SDS TSM
Subscribe for More Information
05:33 EDTSYTSyngenta upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
July 15, 2014
07:29 EDTTSMASML Q2 results could miss expectations, says RBC Capital
Subscribe for More Information
05:37 EDTRHHBYGenentech Avastin granted priority review by FDA
Subscribe for More Information
July 14, 2014
14:20 EDTATHNathenahealth July volatility increases into Q2 and outlook
Subscribe for More Information
11:20 EDTRHHBYExelixis seen as potential target for Roche, TheStreet says
Subscribe for More Information
July 10, 2014
10:02 EDTRHHBYRoche unit, Merck KGaA to develop companion test for cancer treatment
Ventana Medical Systems, a member of the Roche Group (RHHBY), announced it has entered into an agreement with Merck KGaA (MKGAY), which operates as EMD Serono in the United States and Canada, to collaborate with Merck KGaA's biopharmaceutical division on the development and commercialization of a companion diagnostic for an undisclosed target using Ventana's proprietary diagnostic assays.
08:55 EDTATHNathenahealth volatility increases into Q2 and outlook
Subscribe for More Information
07:54 EDTTSMTSMC begins shipping microprocessors to Apple, WSJ reports
TSMC (TSM) has begun shipping microprocessors to Apple (AAPL) for use in smartphones and tablets, reports the Wall Street Journal. According to people familiar with the matter, TSMC began shipping the microprocessors in Q2 and agreed to work together on more advanced chips next year. Reference Link
07:11 EDTAETAetna, WellPoint top large-cap Managed Care picks at Jefferies
Jefferies calls Aetna (AET) and WellPoint (WLP) its favorite large-cap picks in the Managed Care space, with Health Net (HNT) its favored name in the small to mid-cap space. The firm believes the market is already expecting strong Q2 results from the sector, and it downgraded UnitedHealth (UNH) to Hold from Buy on valuation and below-peer earnings growth. Jefferies has Buy ratings on Aetna, Health Net, Molina Healthcare (MOH) and WellPoint.
06:23 EDTAETHealth insurers moving away from fee for service model, NY Times reports
Subscribe for More Information
July 9, 2014
12:56 EDTAETAetna names Harold L. Paz, M.D., M.S. as Chief Medical Officer
Subscribe for More Information
06:15 EDTTSMTSMC to speed up development of 19nm process, DigiTimes reports
Subscribe for More Information
July 8, 2014
07:17 EDTRHHBYLeerink raises immuno-oncology market forecast to $36B
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use